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This issue of the Journal provides the eagerly anticipated
formal report of the North American Vasovagal Pacemaker
Study. The communication is notable for several reasons. First,
although prior reports had suggested a possible benefit of
pacing in patients with vasovagal syncope (1–4), none were
randomized or controlled studies. Consequently, the observa-
tion in the North American Study that cardiac pacing was so
effective in diminishing risk of syncope recurrences in highly
symptomatic vasovagal fainters remained a surprise. If sub-
stantiated, such a finding could markedly alter treatment
strategy in these patients. Second, the end points examined in
this report were more sophisticated than have typically been
used in syncope studies heretofore. Specifically, both syncope
recurrence and the duration of the asymptomatic interval to
first recurrence (a methodology that has become widely ac-
cepted in the evaluation of antiarrhythmic drugs [5–7]) were
reported. Third, this is the first multicenter randomized study
examining a treatment strategy in patients with vasovagal
syncope to be reported in its entirety; as such, it is a refreshing
departure from the many nonrandomized uncontrolled studies
that comprise the bulk of the literature on this topic.
See page 16
The North American Vasovagal Pacemaker Study was an
ambitious project given the considerable uncertainty at the
time of its initiation that pacemakers had any role to play in
treating vasovagal syncope patients. The goal of the study as
stated in the Introduction was to examine the hypothesis that
“a decision to implant a pacemaker” would reduce the risk of
syncope in a group of patients at high risk of vasovagal syncope
recurrences. However, it seems clear that all enrolled patients
had to have wrestled with and had to be ready to accept the
notion of pacemaker implantation before randomization (only
one patient who was randomized to a pacemaker subsequently
refused to proceed). Thus, the “decision” process was a
prerequisite for all candidates. The treatment effect being
tested was, as is more accurately stated in the Abstract, the
pacemaker implantation itself. The control group did not
undergo a surgical procedure with all its attendant real and
psychologic impact, in addition to the additional care and
follow-up that a pacemaker requires. Further, although the
findings indicate reduced syncope risk in pacemaker-implanted
patients, the study design did not permit obtaining direct
evidence that it was the pacing (in this case with a “rate-drop
response feature”) that did the trick. To be fair, the investiga-
tors acknowledge these limitations. In regard to controlling for
the implantation itself, investigators provide an eminently
reasonable defense that the knowledge base at the time was
too shaky to justify device placement in all candidates. In
addition, they argue that the absence of any reduction of
presyncope frequency in paced patients essentially obviated
concerns regarding the “pacemaker placebo” effect. Neverthe-
less, the principal result cannot yet be considered cast in stone,
and for now the clinician must live with doubts that future
studies will need to address.
Apart from global issues raised by the study design, a
number of other features of the study warrant attention. The
inclusion criteria required multiple faints (at least six) as well
as a positive tilt-table test in which bradycardia (meeting a
predetermined standard) was documented. The duration of
time over which the faints had occurred is not expressly stated,
but given a median lifetime history of 35 events, it seems
reasonable to conclude that the symptomatic period was long,
and as such the enrolled patients comprise a relatively high-
risk group (8). Clearly, stringent symptom criteria helped
justify the offer of pacemaker implantation despite consider-
able uncertainty as to its value, and also accelerated determi-
nation of any treatment effect. However, as the investigators
point out, these were not the average vasovagal fainter. The
reader needs to be alert to the very symptomatic nature of the
study population when considering clinical application of the
results. In addition, the study does not permit making any
statement regarding the relative merits of pacing versus “con-
ventional” pharmacologic approaches in these patients. Little
is stated regarding the aggressiveness with which prior medical
therapy had been pursued, or the criteria for failure of prior
medical treatment. It appears that only 32 of the 54 patients
had received drug treatment (principally beta-adrenergic
blockers or disopyramide). Other possibly more effective
agents, such as midodrine, may not have been available at the
time of the study. Nevertheless, such therapies need to at least
be considered by the clinician before pursuing a pacemaker for
vasovagal faints. Furthermore, the treatment of the nonpaced
control group appears to have been at best haphazard. The
investigators may argue that it was immaterial vis-a`-vis the
study goal. In contrast, absent such a comparison, the reader is
left in limbo. It would have been of interest to have selected a
single (albeit arbitrary) drug regimen for comparison. Finally,
the report does not indicate clearly the distribution of patient
enrollment across the multiple participating centers. Pre-
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publication of the data suggests that the vast majority of
enrollees came from two sites, and many centers made little or
no contribution to the patient population. Consequently, the
impact of local treatment biases on study outcome cannot be
excluded.
The ultimate impact of the North American Vasovagal
Pacemaker Study on pacing practice remains to be seen.
Guidelines from several major professional societies (Ameri-
can College of Cardiology/American Heart Association [9],
British Pacing and Electrophysiology Working Group [10])
already provide a class II indication for pacing in vasovagal
syncope, and the North American Study may substantially
increase the frequency with which this indication is cited.
Nevertheless, a number of factors may, at least for the time
being, limit physician enthusiasm for the pacemaker option.
Most importantly, the average vasovagal syncope patient is
relatively young, and consequently would be exposed to pacing
and its hassles (follow-up, device problems and replacements)
for a long time. Second, there is reasonable concern regarding
our ability to discern the relative contributions of cardioinhib-
itory and vasodepressor features of the faint in individual
patients. Currently, tilt-table testing is the only widely available
approach to this issue, and was relied upon in the North
American Study. However, the relationship between observa-
tions during tilt-table induced faints, and the pathophysiology
of spontaneous syncopal events in the same patient (i.e., the
relative magnitudes of cardioinhibitory and vasodepressor
contribution), has yet to be studied adequately. This limitation
is crucial, because a detectable cardioinhibitory component is
needed to even trigger the pacing operation (at least for
current generation devices). Furthermore, substantial brady-
cardia would seem to be an important aspect of spontaneous
clinical events for pacing to be useful. It seems unlikely that
even relatively rapid pacing could ameliorate a marked vaso-
depressor element to any important extent. Conversely, not all
bradycardic events (including some relatively abrupt drops in
heart rate) equate to vasovagal faints even in highly susceptible
patients. Comparable rate changes may occur, for instance,
during sleep or even with marked sinus arrhythmia. Finally, it
remains uncertain whether spontaneous vasovagal events al-
ways exhibit the same pathophysiological features in a given
individual. Findings during repeated tilt-table-induced faints
have been at odds on this issue. For instance, Chen et al. (11)
reported a strong correlation between heart rate and hemody-
namic findings in each of two sequential head-up tilt tests
undertaken on the same day. These investigators suggested
that the characteristics of the induced episodes were generally
reproducible within a given patient. In contrast, Fish et al. (12)
found that, although syncope or presyncope was reproduced by
tilt-table testing in the majority of cases (67%), the pattern of
physiologic response (i.e., cardioinhibitory, vasodepressor,
mixed) varied. Thus, they raised the concern that the physio-
logic pattern may be variable in the same patient. Further
clarification of this issue by even more careful evaluation of
moment-to-moment heart rate and blood pressure changes is
needed.
What then should be the role for pacemaker therapy in
treatment of vasovagal syncope in the year ahead? Clearly, for
most vasovagal syncope patients, education to facilitate recog-
nition and avoidance of provoking events, along with support-
ive reassurance, remain essential first steps in the treatment
strategy. In fact, usually these steps are all that are needed.
However, when more than these basic measures are necessary,
pharmacologic approaches (perhaps someday supported by
randomized trials comparable in quality to the North Ameri-
can Vasovagal Pacemaker Study) are likely to remain more
appealing than cardiac pacing for most patients. In this regard,
various drugs have been thought to be helpful for prevention of
recurrent vasovagal faints (13–24). Beta-adrenergic blockers,
disopyramide, certain vasoconstrictor agents (e.g., etilephrine,
midodrine), and serotonin reuptake inhibitors have been of
greatest interest. However, for any of these agents, current
experience is largely limited to small nonrandomized and
uncontrolled studies in which syncope recurrence is the only
recorded end point. Other end points, such as time to first
recurrence, asymptomatic interval and total syncope “burden”
(i.e., the number of events per unit time) have yet to be
assessed. In any event, if at this stage pharmacologic treatment
is deemed to have failed (based on end points for which a
consensus needs to be developed) or not to be tolerable, one
might reasonably consider the addition of cardiac pacing with
some form of rate-drop response and high-rate pacing feature.
Currently, it seems prudent to place a conservative spin on
the present status of cardiac pacing in vasovagal syncope.
However, it would not be appropriate to cast an excessively
negative shadow on what may be a very promising treatment
avenue; physicians should not be so reluctant to use pacing that
important treatment opportunities are missed. They must be
cognizant of the fact that, while vasovagal faints are most often
“benign,” recurrent vasovagal symptoms may cause unwanted
lifestyle changes in some individuals (e.g., loss of indepen-
dence, excessive health insurance premiums, restriction of
driving privilege) and predispose them to injury or accidents.
Additionally, prevention of even infrequent faints may be
essential for certain occupations (e.g., airline pilots, commer-
cial vehicle operators, critical-care medical personnel) or avo-
cations (e.g., mountaineers, skiers).
In conclusion, the North American Vasovagal Pacemaker
Study has contributed importantly to the concept that implan-
tation of a cardiac pacemaker may benefit certain patients with
recurrent troublesome vasovagal syncope. For now, however,
the take-home message is one of careful patient selection with
cautious optimism regarding treatment benefit. Ultimately, if a
number of important barriers can be overcome, pacing for
treatment of recurrent troublesome vasovagal syncope may
become more common. These barriers include 1) confirmation
that symptomatic benefit is clearly attributable to the pacing
intervention, 2) development of pacing algorithms that permit
specific and sensitive recognition of vasovagal syncope at a
relatively early stage in an evolving episode, 3) documentation
that the benefits of pacing (i.e., prolonging asymptomatic
intervals, reducing symptom severity) are maintained over the
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long term, and 4) arriving at a consensus regarding the
definition of treatment “failure” and treatment “success”
(recognizing, of course, that individualization of such stan-
dards will always be important).
The author would like to thank Wendy Markuson for preparation of the
manuscript.
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